Real world outcomes using PD ‐1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

ISSN
0926-9959
Date Issued
2022
Author(s)
Schumann, K.
Mauch, C.
Klespe, K. C.
Loquai, C.
Nikfarjam, U.
Schlaak, M.
Akcetin, L.
Kölblinger, P.
Hoellwerth, M.
Posch, C.
DOI
10.1111/jdv.18779